Under the auspices of the European Policy Roundtable on Smoking Cessation, initiated and funded by Pfizer, 15 experts on tobacco dependence and control urge policy makers across Europe to prioritize the continued implementation of the WHO Framework Convention on Tobacco Control (FCTC) in the interest of public health.

Together, we call on policy makers to take action to reduce the human, societal and economic burden of tobacco use by urgently and significantly improving the implementation of Article 14 on tobacco dependence and cessation. Only through improving the implementation will we achieve a decrease in mortality and morbidity associated with tobacco use.

The burden of tobacco on morbidity and mortality is preventable and significant, and remains unnecessarily high in Europe. Progress has been made in introducing policies to reduce the heavy toll of tobacco use on the health and well-being of European citizens. Data from the European Commission's 2015 Eurobarometer report suggest that tobacco use decreased by 2% between 2012 and 2015 ([@R1]). Despite this, tobacco consumption remains the single largest avoidable health risk in Europe ([@R1]) and it is clear that more needs to be done. More than a quarter (26%) of Europeans still smoked in 2014 ([@R1]) and the harm caused by tobacco extends beyond the user to those -- often children -- with no option but to share smokers' space ([@R6]).

There is no 'safe' level of tobacco use. Tobacco use causes illness and death, drains healthcare resources and decreases productivity ([@R2]; [@R1]). It claims 700 000 lives every year in Europe ([@R1]) and an estimated 25.3 € billion of European public healthcare funds are spent annually to treat tobacco-related diseases ([@R1]), while tobacco use costs European productivity a staggering 8.3 € billion ([@R1]).

Tobacco prevention policies aim to stop individuals from starting to smoke. Evidence suggests, however, that strategies focusing wholly on smoking prevention can provide only minimal reductions in tobacco-related morbidity over the next 20 years \[[@R3]\]. It is, therefore, vital to help those who are already dependent on tobacco to quit. The cessation of tobacco use is the only way to achieve the 25% reduction in mortality from noncommunicable diseases before 2025, which was a commitment made at the 2011 UN high-level meeting on noncommunicable diseases ([@R4]).

Tobacco dependence is a WHO-recognized disorder ([@R10]) that can benefit from treatment. Tobacco dependence and addiction make cessation a struggle, even for those with a strong commitment to stopping. Of daily smokers who attempt to quit without support, 96--97% relapse within 12 months ([@R8]). Conversely, smokers who seek help from a healthcare professional are up to four times more likely to successfully quit than those who do not see expert help ([@R7]; [@R5]; [@R8]).

The benefits of support to aid the cessation of tobacco use are widespread, and cessation interventions are 'extremely cost-effective when compared with other healthcare system interventions' ([@R10]). The FCTC Article 14 and its implementation guidelines call on its parties to 'facilitate accessibility and affordability for treatment of tobacco dependence' ([@R10]). According to the 2014 FCTC implementation report, the implementation of services to support cessation of tobacco use in line with Article 14 can and should be significantly improved ([@R12]). Furthermore, the WHO 2015 report on the global tobacco epidemic noted that 'there has been little progress in providing access to essential help to quit smoking' ([@R10]). We believe that it is time for this to change: more urgent steps are required to protect the health of European citizens.

We call on policy makers to continue implementing the WHO FCTC as a public health priority. In line with governments' obligations under the FCTC, we urge them to establish effective services to support cessation of tobacco use available through health systems and insurances to prevent treatment cost acting as a barrier to those who wish to quit.
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